|
| Mechanism of Guchang Capsule in treating inflammatory bowel disease by regulating p38MAPK/NF-κB signaling pathway |
| Hits 32 Download times 7 Received:December 07, 2025 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1673-9043.2026.04.09 |
| Key Words
Guchang Capsule;inflammatory bowel disease;lncRNA THRIL;p38MAPK/NF-κB signaling pathway;inflammatory factor |
| Author Name | Affiliation | E-mail | | WANG Xiaohong | General Hospital of Tianjin Medical University, Tianjin 300052, China | | | LIU Rong | General Hospital of Tianjin Medical University, Tianjin 300052, China | | | WANG Hong | General Hospital of Tianjin Medical University, Tianjin 300052, China | | | SONG Xinlong | General Hospital of Tianjin Medical University, Tianjin 300052, China | | | LIU Baoshan | General Hospital of Tianjin Medical University, Tianjin 300052, China | liubaoshanzyy@163.com |
|
| Abstract
|
| [Objective] To investigate the therapeutic effect of Guchang Capsule on animal models of inflammatory bowel disease（IBD），and to clarify whether it improves IBD by downregulating long non-coding RNA（lncRNA） THRIL and inhibiting the p38 mitogen-activated protein kinase（p38MAPK）/nuclear factor-κB（NF-κB） signaling pathway. [Methods] A total of 36 male C57BL/6 mice were randomly divided into six groups（6 mice per group）：control group，model group，low-dose Guchang Capsule group [500 mg/（kg·d）]，medium-dose Guchang Capsule group [1 000 mg/（kg·d）]，high-dose Guchang Capsule group [1 500 mg/（kg·d）]，and mesalazine group [200 mg/（kg·d）]. Except for the control group，all other groups were induced with IBD by drinking 4% dextran sulfate sodium（DSS） aqueous solution for 7 consecutive days. After successful modeling，each administration group received intragastric administration for 10 consecutive days，while the control group and model group received an equal amount of distilled water. The disease activity index（DAI） score of mice in each group was observed. Hematoxylin-eosin（HE） staining was used to observe pathological changes in colon tissue. Enzyme-linked immunosorbent assay（ELISA） was used to detect the levels of tumor necrosis factor-α（TNF-α），interleukin-6（IL-6），interleukin-1β（IL-1β），interleukin-4（IL-4），and interleukin-10（IL-10） in colon tissue. Quantitative real-time polymerase chain reaction（qRT-PCR） was used to detect the expression of lncRNA THRIL. Western blot and immunohistochemistry were used to detect the expression of p38MAPK/NF-κB pathway-related proteins（p-p38MAPK， p38MAPK，p-p65，p65）. [Results] Compared with the control group，the model group showed significantly decreased body weight（P<0.05），increased DAI score（P<0.05），increased colon tissue pathological score（P<0.05），increased levels of pro-inflammatory factors TNF-α，IL-1β，and IL-6（P<0.05），decreased levels of anti-inflammatory factors IL-4 and IL-10（P<0.05），increased expression of lncRNA THRIL（P<0.05），and increased protein ratios of p-p38MAPK/p38MAPK and p-p65/p65（P<0.05）. Compared with the model group，the medium-dose and high-dose Guchang Capsule groups and the mesalazine group showed significantly increased body weight（P<0.05），decreased DAI score，colon tissue pathological score，and levels of pro-inflammatory factors（TNF-α，IL-1β，IL-6）（P<0.05），increased levels of anti-inflammatory factors（IL-4，IL-10）（P<0.05），and downregulated expression of lncRNA THRIL and protein ratios of p-p38MAPK/p38MAPK and p-p65/p65 in colon tissue（P<0.05）. [Conclusion] Guchang Capsule can improve IBD symptoms by downregulating lncRNA THRIL and inhibiting the activation of the p38MAPK/NF-κB signaling pathway，thereby reducing intestinal inflammatory responses. |
|
